Tamoxifen and AIs are among the first examples of targeted therapies for cancer. These treatments reflect challenges associated with such approaches: for example, the necessity for prolonged and self-administered treatment, and the prevalence of side effects that differ from those associated with standard cancer therapies. Targeted therapies call for a new paradigm for cancer treatment, in which monitoring for adherence will be needed not only by the oncologist, but also by the primary care provider; and where attention to strategies to maintain and enhance the patient's quality of life is critical to ensure that the treatment has its optimal impact.
Expert Rev Pharmacoeconomics Outcomes Res. 2011;11(6):709-715. © 2011 Expert Reviews Ltd.